ArticleApoptosis : an international journal on programmed cell death2026
Identifying Neddylation-modified features to assess prognosis and immune efficacy in hepatocellular carcinoma.
Article in Apoptosis : an international journal on programmed cell death, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The Neddylation pathway is excessively activated in the occurrence and development of various cancers. However, there is currently a lack of comprehensive analysis of the Neddylation pathway in hepatocellular carcinoma (HCC). We treated HCC cells with a Neddylation pathway inhibitor (MLN4924) to observe its effects on the biological functions of HCC cells. Additionally, we constructed a Neddylation-related risk score (NRS) in HCC. Subsequently, we assessed the clinical value of NRS in predicting the prognosis of HCC and the efficacy of immunotherapy. Finally, we investigated the role of Proteasome 26S Subunit, Non-ATPase 1 (PSMD1) in the malignant progression of HCC through in vivo and in vitro experiments. MLN4924 significantly inhibits the proliferation and migratory capacity of HCC cells, promotes apoptosis, and upregulates PD-L1 expression. Moreover, we have confirmed through in vivo and in vitro experiments that MLN4924 can enhance the sensitivity to Sorafenib. Additionally, we found that patients in the high NRS group have poor prognoses and are prone to developing resistance to treatments such as Sorafenib and Oxaliplatin, while being more sensitive to 5-Fluorouracil and immunotherapy. Finally, in both in vitro and in vivo experiments, it was found that knocking down PSMD1 can weaken the proliferation and metastatic capacity of HCC cells. Furthermore, knocking down PSMD1 can inhibit the levels of PD-L1 protein and NEDD8 protein that binds to Cullin in HCC cells. Mechanistically, we found that PSMD1 stabilizes the protein expression of β-catenin by inhibiting its degradation through the ubiquitin-proteasome system, thereby influencing the expression of PD-L1. In conclusion, this study reveals that Neddylation-related characteristics can effectively predict the prognosis and immunotherapy outcomes of HCC. Furthermore, targeting PSMD1 may represent a potential therapeutic approach for HCC.
Indexed as
Identifiers
42178458What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.